IV and inhaled VIP gave mixed results in three severe COVID-19 trials

What is vasoactive intestinal peptide?

Vasoactive intestinal peptide (VIP) is an endogenous 28-amino-acid neuropeptide in the secretin/glucagon family, released from neurons throughout the gut, lungs and central nervous system. VIP signals through two G-protein-coupled receptors, VPAC1 and VPAC2, which are expressed widely on smooth muscle, epithelial cells and immune cells.

Receptor activation raises intracellular cAMP. Higher cAMP relaxes smooth muscle, which produces vasodilation and bronchodilation, and it modulates cytokine release in ways generally described as anti-inflammatory or immune-tolerizing.

This physiology is legitimate and well characterized. None of it shows that a nasal VIP spray treats a mold-exposure syndrome.

Why was VIP tested in COVID-19?

VIP was tested in severe COVID-19 because its receptor pharmacology made it a reasonable hypothesis for acute lung injury. Hypoxemia and inflammatory overdrive are the two things killing patients with severe COVID-19, and a molecule that dilates pulmonary vasculature and dampens cytokine storms is a plausible candidate against both.

That research thread produced the three aviptadil trials described below. It has nothing to do with a low-dose, sinus-delivered peptide used in a home protocol for a mold-exposure syndrome.

Has VIP been tested for mold illness or CIRS?

No completed human trial has tested VIP by any route in mold illness, CIRS or tissue repair. None of the trials cited below tested VIP for immune modulation in chronic illness either.

Most protocol write-ups blend VIP's evidence into one narrative. Separated, it falls into three tiers, and D, limited, is the ceiling:

• Human randomized trials. Three trials tested IV or inhaled aviptadil in acute COVID-19 respiratory failure ^[1]⁠^[2]⁠^[3].
• Cell culture. One in vitro study found faster epithelial wound healing in a single cell type ^[4].
• Protocol lore. Everything else comes from one clinician's proprietary CIRS framework, not from independently replicated research.

VIP's baseline receptor pharmacology is real. The nasal protocol built on top of it lacks the evidence needed to move above a D.

Is CIRS a recognized diagnosis?

Chronic inflammatory response syndrome (CIRS) is not a recognized diagnosis in mainstream immunology. CIRS originates from a single clinician's proprietary protocol and lab panel, not from peer-reviewed diagnostic consensus.

The protocol's claims about MSH deficiency, HLA-DR genetic susceptibility, and VIP as a "master regulator" correctable with titrated nasal dosing all come from that proprietary diagnostic framework. Outside labs have not validated the framework. The lab panel and questionnaire that anchor a CIRS diagnosis are not standard immunology tools.

What did the aviptadil COVID-19 trials find?

Three randomized trials of aviptadil in acute COVID-19 respiratory failure produced mixed results: one missed its primary endpoint, one was stopped for futility, and one small inhaled trial was positive.

• US multicenter trial, IV, 196 patients. IV aviptadil in critical COVID-19 respiratory failure missed the prespecified 60-day primary endpoint, alive and free from respiratory failure. The trial found a statistically significant doubling of 60-day survival odds (OR 2.0, 95% CI 1.1-3.9, p=0.035) and reduced IL-6 in a subset analysis ^[1].
• TESICO, IV, 461 patients at 28 US sites. TESICO tested IV aviptadil plus remdesivir against placebo in hypoxemic COVID-19 respiratory failure. It found no significant benefit on the primary 90-day ordinal outcome and was stopped early for futility ^[2].
• Turkish trial, inhaled, 80 patients. Inhaled, not IV, aviptadil produced a modest but statistically significant reduction in time to hospital discharge (7.8 vs 10 days, p=0.049) and better CT-scored lung recovery at 28 days ^[3], with no dropouts attributed to side effects.

Even in this narrow lane, aviptadil carries an open research question in a single acute illness; it is not a peptide with proven efficacy. Its trial formulations, doses and delivery systems bear no resemblance to a self-administered nasal spray.

Does VIP help repair tissue?

VIP sped wound closure in cultured human bronchial epithelial cells ^[4], but no completed human trial has tested VIP for wound healing or tissue regeneration.

In that 2006 cell-culture study, VIP also accelerated cell migration. A VPAC1 antagonist blocked the effect, which was linked to increased E-cadherin expression ^[4]. The finding is real and receptor-specific. It also comes from one epithelial cell type with peptide applied directly in a dish, far removed from any human dosing protocol, and cell culture generates hypotheses rather than confirming them.

Is there an evidence-based dose for intranasal VIP?

None of the aviptadil trials supports an intranasal VIP dose, because none used the intranasal route or studied people self-treating mold illness.

The IV and inhaled routes and delivery patterns from those trials do not validate a self-directed nasal regimen. How much of a nasal dose reaches its target is a separate question; how nasal peptides reach the brain covers the narrow pathways involved.

What are the side effects of VIP?

VIP's side effects follow from its action as a potent vasodilator: flushing, hypotension, headache and dizziness are reported across the studied contexts.

In the unrelated erectile-dysfunction combination product, VIP plus phentolamine given intracavernosally, reports include low rates of penile pain and a very low priapism risk. Nasal irritation is reported with intranasal use generally.

VIP's primary, best-documented effect is dropping vascular tone. Lightheadedness, blood pressure drops and tachycardia are the plausible harms, and they deserve the same weight as the promised benefits, which rest on narrative rather than randomized trial data outside acute respiratory failure.

Product quality adds a separate risk. Anything compounded or sold "research use only" carries gray-market quality risk, and how to read a peptide certificate of analysis covers what a lab report can and cannot confirm.

What is still unknown about VIP for mold illness?

The core questions behind a nasal VIP protocol have not been answered:

• Mold-related endpoints. Whether VIP by any route produces a measurable, reproducible effect on inflammatory markers, symptom burden or any endpoint relevant to mold exposure or CIRS in humans is unknown.
• Intranasal receptor engagement. Whether intranasal dosing achieves systemically meaningful receptor engagement, given VIP's short half-life, is unknown.
• The MSH/VIP deficiency model. Its independent diagnostic validity is unstudied outside its originating protocol.
• Tissue repair in vivo. Whether the wound-healing signal in cultured bronchial cells ^[4] translates to any human tissue-repair outcome is untested in vivo.
• Aviptadil in respiratory failure. Whether aviptadil has a real role even in acute respiratory failure remains unresolved, given the conflicting results across the three trials ^[1]⁠^[2]⁠^[3].

That last question concerns a pharmaceutical-grade, clinically monitored IV or inhaled formulation studied in critically ill hospitalized patients, several steps removed from a compounded nasal spray used at home.